Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ivermectin for onchocercal eye disease (river blindness).

H Ejere1, E Schwartz, R Wormald

  • 1International Health Division, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK, L3 5QA. hodejere@liv.ac.uk

The Cochrane Database of Systematic Reviews
|May 2, 2001
PubMed
Summary

Ivermectin, a treatment for onchocerciasis, has not been proven to prevent vision loss in affected individuals. More research is needed to clarify its effectiveness in preventing visual acuity loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Nursing knowledge production in Argentina, Chile, Paraguay and Uruguay].

Revista gaucha de enfermagem·2002
Same author

Repeated inoculation as a strategy for the remediation of low concentrations of phenanthrene in soil.

Biodegradation·2002
Same author

The changing epidemiology of leptospirosis in Israel.

Emerging infectious diseases·2001
Same author

Lesions in the central nucleus of the amygdala: discriminative avoidance learning, discriminative approach learning, and cingulothalamic training-induced neuronal activity.

Neurobiology of learning and memory·2001
Same author

CT of noninfectious granulomatous lung disease.

Radiologic clinics of North America·2001
Same author

Results of trachoma rapid assessment in 11 villages of South Gonder zone, Ethiopia.

Tropical doctor·2001

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Onchocerciasis, a parasitic infection, can lead to blindness.
  • Ivermectin is a microfilaricide used to treat onchocerciasis.
  • The drug's impact on ocular lesions and prevention of visual loss remains uncertain.

Purpose of the Study:

  • To evaluate ivermectin's effectiveness in preventing visual acuity and field loss in onchocercal eye disease.
  • To assess ivermectin's effects on ocular lesions associated with onchocerciasis.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) with at least one-year follow-up.
  • Included trials compared ivermectin (150 µg/kg) against placebo or no treatment.
  • Data extraction and quality assessment were performed independently by two reviewers.

Related Experiment Videos

Main Results:

  • Five RCTs with 3810 participants were included, all comparing ivermectin to placebo.
  • Trials had a moderate risk of bias.
  • No statistically significant difference in visual acuity loss was observed between ivermectin and placebo groups.

Conclusions:

  • The available evidence does not definitively answer whether ivermectin prevents visual acuity loss in onchocerciasis.
  • Further research is required to establish the efficacy of ivermectin for preventing vision impairment in ocular onchocerciasis.